- Fecal Incontinence
This activity has been designed to meet the educational needs of primary care providers, physician assistants, and nurse practitioners involved in the care of patients with irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC).
Upon completion of this activity, participants should be better able to:
Describe the burden of IBS and CIC on patients and the health care system
Discuss new and emerging diagnostic strategies and therapies for IBS and CIC
Describe the evidence base regarding the efficacy and safety of conventional and newer therapies for IBS and CIC
Differentiate among newer therapies for IBS and CIC with regard to pharmacology, efficacy, safety, and tolerability
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements andpolicies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Cincinnati and the Gi Health Foundation. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: May 1, 2018Expiration Date: May 31, 2019 EXPIRED
Physician Disclosure Statement
All faculty and staff involved in the planning or presentation of continuing education activities provided by the University of Cincinnati are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, Gi Health Foundation staff, and the University of Cincinnati staff have no relationships to disclose.
This supplement is supported by Supported by educational grants from Allergan, Inc., Commonwealth Diagnostics International, Inc., Ironwood Pharmaceuticals, Inc., and Salix Pharmaceuticalsan educational grant from Pfizer, Inc.